1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
3
|
Van Cutsem E and Oliveira J; ESMO
Guidelines Working Group: Advanced colorectal cancer: ESMO clinical
recommendations for diagnosis, treatment and follow-up. Ann Oncol.
20(Suppl 4): 61–63. 2009.PubMed/NCBI
|
4
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Wheelock MJ, Shintani Y, Maeda M, Fukumoto
Y and Johnson KR: Cadherin switching. J Cell Sci. 121(Pt 6):
727–735. 2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Le Bras GF, Taubenslag KJ and Andl CD: The
regulation of cell-cell adhesion during epithelial-mesenchymal
transition, motility and tumor progression. Cell Adh Migr.
6:365–373. 2012. View Article : Google Scholar : PubMed/NCBI
|
8
|
He X, Chen Z, Jia M and Zhao X:
Downregulated E-cadherin expression indicates worse prognosis in
asian patients with colorectal cancer: Evidence from meta-analysis.
PLoS One. 8:e708582013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Lee SH, Kim H, Hwang JH, et al: CD24 and
S100A4 expression in resectable pancreatic cancers with earlier
disease recurrence and poor survival. Pancreas. 43:380–388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Huang Z, Zhang N, Zha L, et al: Aberrant
expression of the autocrine motility factor receptor correlates
with poor prognosis and promotes metastasis in gastric carcinoma.
Asian Pac J Cancer Prev. 15:989–997. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Fan M, Liu Y, Xia F, et al: Increased
expression of EphA2 and E-N cadherin switch in primary
hepatocellular carcinoma. Tumori. 99:689–996. 2013.
|
12
|
Lascombe I, Clairotte A, Fauconnet S,
Bernardini S, Wallerand H, Kantelip B and Bittard H: N-cadherin as
a novel prognostic marker of progression in superficial urothelial
tumors. Clin Cancer Res. 12:2780–2787. 2006. View Article : Google Scholar : PubMed/NCBI
|
13
|
Yi S, Yang ZL, Miao X, et al: N-cadherin
and P-cadherin are biomarkers for invasion, metastasis and poor
prognosis of gallbladder carcinomas. Pathol Res Pract. 210:363–368.
2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yamauchi M, Yoshino I, Yamaguchi R, et al:
N-cadherin expression is a potential survival mechanism of
gefitinib-resistant lung cancer cells. Am J Cancer Res. 1:823–833.
2011.PubMed/NCBI
|
15
|
Gao P, Xing AY, Zhou GY, et al: The
molecular mechanism of microRNA-145 to suppress invasion-metastasis
cascade in gastric cancer. Oncogene. 32:491–501. 2013. View Article : Google Scholar
|
16
|
Hulit J, Suyama K, Chung S, et al:
N-cadherin signaling potentiates mammary tumor metastasis via
enhanced extracellular signal-regulated kinase activation. Cancer
Res. 67:3106–3116. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Zhang X, Liu G, Kang Y, Dong Z, Qian Q and
Ma X: N-cadherin expression is associated with acquisition of EMT
phenotype and with enhanced invasion in erlotinib-resistant lung
cancer cell lines. PLoS One. 8:e576922013. View Article : Google Scholar : PubMed/NCBI
|
18
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: a convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
20
|
Findlay VJ, Wang C, Watson DK and Camp ER:
Epithelial-to-mesenchymal transition and the cancer stem cell
phenotype: insights from cancer biology with therapeutic
implications for colorectal cancer. Cancer Gene Ther. 21:181–187.
2014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Micalizzi DS, Farabaugh SM and Ford HL:
Epithelial-mesenchymal transition in cancer: parallels between
normal development and tumor progression. J Mammary Gland Biol
Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI
|
22
|
Toiyama Y, Yasuda H, Saigusa S, Tanaka K,
Inoue Y, Goel A and Kusunoki M: Increased expression of Slug and
Vimentin as novel predictive biomarkers for lymph node metastasis
and poor prognosis in colorectal cancer. Carcinogenesis.
34:2548–2557. 2013. View Article : Google Scholar : PubMed/NCBI
|
23
|
Tanaka H, Kono E, Tran CP, et al:
Monoclonal antibody targeting of N-cadherin inhibits prostate
cancer growth, metastasis and castration resistance. Nat Med.
16:1414–1420. 2010. View
Article : Google Scholar : PubMed/NCBI
|
24
|
Mariotti A, Perotti A, Sessa C and Rüegg
C: N-cadherin as a therapeutic target in cancer. Expert Opin
Investig Drugs. 16:451–465. 2007. View Article : Google Scholar : PubMed/NCBI
|
25
|
Su Y, Li J, Witkiewicz AK, Brennan D,
Neill T, Talarico J and Radice GL: N-cadherin haploinsufficiency
increases survival in a mouse model of pancreatic cancer. Oncogene.
31:4484–4489. 2012. View Article : Google Scholar
|
26
|
Augustine CK, Yoshimoto Y, Gupta M, et al:
Targeting N-cadherin enhances antitumor activity of cytotoxic
therapies in melanoma treatment. Cancer Res. 68:3777–3784. 2008.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Perotti A, Sessa C, Mancuso A, et al:
Clinical and pharmacological phase I evaluation of Exherin™(ADH-1),
a selective anti-N-cadherin peptide in patients with
N-cadherin-expressing solid tumours. Ann Oncol. 20:741–745. 2009.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Yarom N, Stewart D, Malik R, Wells J,
Avruch L and Jonker DJ: Phase I clinical trial of Exherin (ADH-1)
in patients with advanced solid tumors. Curr Clin Pharmacol.
8:81–88. 2013.
|
29
|
Turley RS, Tokuhisa Y, Toshimitsu H, et
al: Targeting N-cadherin increases vascular permeability and
differentially activates AKT in melanoma. Ann Surg. 261:368–377.
2015. View Article : Google Scholar
|